Prostate Cancer Biorepository Network (PCBN)
Technical Report,30 Sep 2018,29 Sep 2019
New York University School of Medicine New York United States
Pagination or Media Count:
The goal of this proposal is to contribute to the continued development of infrastructure and operations of the Prostate Cancer Biorepository Network PCBN. A prostate cancer biorepository fulfils an important need to enable prostate cancer research to be conducted by the wider research community through making readily available clinical biospecimens. Only few academic centers with high volume prostate cancer clinical services and an already developed banking infrastructure are well positioned to enable biospecimen collection. An external funding source as provided by the DOD enables support for the consortium of institutional biorepositories of the PCBN to provide to the wider research community. The major goal of the PCBN is to develop a biorepository with high-quality, well-annotated biospecimens obtained in a systematic, reproducible fashion using optimized and standardized protocols. A main focus of the PCBN is to accrue biospecimens that are in limited supply and documented to be most needed by the prostate cancer community e.g. castration-resistant disease, metastatic disease, primary untreated de novo metastatic disease, high-risk disease, tumors of the aggressive variant phenotype, disproportionately affected populations. The PCBN is funded as a consortium of participating network sites that include New York University, University of Washington, Washington University, Institute of Cancer Research United Kingdom and overall guidance of the coordinating center at Johns Hopkins University. The goal of the NYU network site is to collaboratively contribute toward the PCBN goals, through participation in infrastructure development, biospecimen accrual and derivative product development for the purpose of disbursement to investigators to enhance prostate cancer research.
- Medicine and Medical Research